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Advancing Cancer Immunotherapy  
Through State-of-the-Art  
Translational Research
2015 
YEAR IN REVIEW
Earle A. Chiles  
Research Institute,  
a division of  
Providence Cancer Center
The Earle A. Chiles Research Institute is a world-class  
research facility located within Providence Cancer Center 
in Portland, Ore. Home to a team of internationally- 
recognized scientists and physicians, the main area of  
investigation is cancer immunotherapy.
Location & Contact
Earle A. Chiles Research Institute 
Providence Portland Medical Center 
4805 NE Glisan Street, 2N35 
Portland, OR 97213 
503-215-6588
www.chilesresearch.org
 @ChilesResearch
 @providencecancercenter
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3For the past 23 years,  
our major focus has been  
cancer immunotherapy  
– the hypothesis that the 
immune system can be  
activated to recognize  
and kill cancer cells. 
Immunotherapy is not a new  
concept. It has been the subject of 
investigation for more than 100 years. 
There has always been a strong 
scientific rationale for immunotherapy, 
but until recently there was little 
evidence of clinical benefit. Tumor 
regressions were so uncommon that, when we started 23 years 
ago, the idea that physicians would be able to harness the body’s 
immune system to fight cancer was met with skepticism. 
Nevertheless, we believed in the power of the immune system and 
refused to abandon what we thought was a promising strategy. 
With the support of Providence Health & Services, philanthropists, 
public and private grants, and industry partners, we built a great 
team and continued to learn more about the immune system  
and cancer biology. Armed with this knowledge, we were able to 
move our innovations from the laboratory to the patient bedside. 
The best example of our novel approach is the OX40-based  
translational research led by Andrew D. Weinberg, Ph.D., (page 
25) and Brendan D. Curti, M.D. (page 15). The OX40 discovery 
research performed at our institute was fueled by local  
MESSAGE FROM THE DIRECTOR
philanthropy, which allowed us to initiate the first-in-human  
OX40 trial at Providence Cancer Center, and led to the formation  
of the biotechnology company, AgonOx. Providence licensed the 
technology to AgonOx, who sublicensed OX40 to one of the  
largest pharmaceutical companies in the world. What began as a 
philanthropy-driven 30-patient trial in a single hospital in Portland, 
Ore. is now being tested in hundreds of patients in multiple cancer 
centers around the world.
We are also proud of our contribution to the development of 
ipilimumab – the first immunotherapy drug to improve survival  
in patients with advanced melanoma. I was honored to serve  
as the principal investigator for the international clinical trial that  
led to ipilimumab’s FDA approval in 2011, distinguishing the Earle 
A. Chiles Research Institute as a leader in cancer immunotherapy. 
In the past 10 years, we have witnessed more progress in  
cancer care than in the previous 100 years. When we began,  
immunotherapy was the focus of only a handful of centers.  
Now it is a major program in every cancer center in the United 
States and a top priority in every major drug company. There is no 
denying that this is a very exciting time in cancer research. However, 
despite the significant progress that has been made, substantial 
challenges remain because only a minority of patients with  
advanced cancer benefit from current therapy. 
Every advance in the treatment of cancer is the result of our  
investment in research, the teams of scientists and physicians  
attempting new approaches and the incredibly brave patients who 
volunteer to help move us forward. We are grateful for our many 
supporters who have partnered with us, and we invite you to help 
us acheive our goal of increasing the number of cancer survivors 
through immunotherapy. Together, we can finish cancer. 
Walter J. Urba, M.D., Ph.D.
Member, director and endowed 
chair of Cancer Research
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FACTS & FIGURES
Investigators & Personnel Grant Funding, Sponsored  
Research & Philanthropy
	 n $3.4 million annually  
  in federal, private and  
  sponsored research funding
 n Providence Foundations  
  Center of Hope Campaign   
  raised over    
  for cancer research, including  
  a gift of $5.5 million
 n Providence Guest   
  House opened to patients   
  and their families through   
  philanthropic support
Clinical Trials
	 n 214 cancer clinical trials  
  open for enrollment,  
  including  therapeutic   
  trials and 51 Phase I trials 
	 n  total enrollments
Memberships & Collaborations
	 n  Bristol Myers-Squibb  
  International      
  Immuno-Oncology Network	
	 n NCI Cancer Immunotherapy   
  Trials Network
	 n NCI Community Oncology   
  Research Program
	 n Partnership with MedImmune /  
  AstraZeneca for the clinical  
  development of anti-OX40
	
   
Institute Publications
n Journal    
  Articles:
44 8
n Book  
   Chapters:
56
	 n Abstracts:
n Faculty  
   Members:18
n Clinical  
  Researchers:32
n Lab  
  Researchers: 46
Dr. Kristina Young, Dr. Walter 
Urba and Dr. David Page with 
2015 ASCO Young Investigator 
Award plaques.
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New Faculty Appointments
Kristina H. Young, M.D., Ph.D., and David B. Page, M.D., 
are the two newest physician researchers to join  
the Earle A. Chiles Research Institute, and both have  
received national recognition. In 2015, they were 
among 58 recipients worldwide to be honored with a 
Young Investigator Award from the American Society 
of Clinical Oncology. 
Dr. Young is a radiation oncologist 
with a laboratory research focus on 
the tumor microenvironment. She 
completed her medical education, 
residency and doctoral degree in 
cellular and developmental biology 
at Oregon Health & Science  
University, and completed a  
Holman Research Pathway  
Fellowship in the investigation  
of radiation oncology and basic 
science at the Earle A. Chiles 
Research Institute. Read more about Dr. Young on page 26.
Dr. Page is a medical oncologist specializing in new immunotherapies 
for women with breast cancer. After completing his medical 
education at Northwestern University Feinberg School of Medicine 
and residency at New York Presbyterian Hospital / Columbia 
University Medical Center, he completed a medical oncology 
fellowship at Memorial Sloan Kettering Cancer Center. Read  
more about Dr. Page on page 22. 
NEW & NOTEWORTHY
Noteworthy Studies & Publications
In collaboration with Dung Le, M.D., of Johns Hopkins University, 
Todd S. Crocenzi, M.D., was co-investigator on a Phase II study 
of PD-1 inhibition in patients with metastatic colorectal cancer. 
This landmark study showed that anti-PD-1 was effective in  
this subset of patients with advanced colon cancer and defects  
in mechanisms of DNA repair. This research helped make the  
important correlation between mutational burden and efficacy  
of immunotherapy (N Engl J Med. 2015; 372(26):2509).  
Read more about Dr. Crocenzi on page 14.
Bernard A. Fox, Ph.D, with Carlo B. Bifulco, M.D., led an  
international task force evaluating the prognostic value of  
the immune score in patients with colorectal cancer. With the  
aid of his graduate student, Zipei Feng, multispectral imaging  
was used to predict the ability to culture tumor-infiltrating  
lymphocytes and the results were presented at major scientific 
conferences. Learn more about Dr. Fox on page 16 and  
Dr. Bifulco on page 11.
Brendan D. Curti, M.D., was co-author on the seminal  
publication Talimogene Laherparepvec Improves Durable  
Response Rate in Patients with Advanced Melanoma, which  
led to FDA approval of this innovative oncolytic therapy in  
October 2015 (J Clin Oncol. 2015; 33(25):2780). Read more 
about Dr. Curti on page. 15.
Rachel E. Sanborn, M.D., served as the Providence Cancer 
Center site principal investigator for the clinical trial testing 
anti-PD-1(nivolumab) in patients with advanced squamous  
non-small cell lung cancer. Following successful trial results, 
nivolumab received FDA approval in March 2015, earlier than 
… continued
Dr. Walter Urba, Caryn Urba, Steve Harder, Cindy Harder, Lori Fox and 
Dr. Bernard Fox
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anticipated, culminating in the first immunotherapy drug  
approval for lung cancer. Later in October, the FDA expanded 
approval of nivolumab to include previously treated patients  
with advanced non-squamous non-small cell lung cancer.  
Read more about Dr. Sanborn on page 24.
Preclinical work from the laboratory of William L. Redmond, 
Ph.D., has shown the benefit of combining checkpoint  
inhibitors, such as anti-CTLA-4 or anti-PD-1, with a galectin-3 
inhibitor (GR-MD-02). This led to two translational clinical  
trials testing the galectin inhibitor in combination with  
checkpoint inhibitors, supported in part by an R21 grant  
award from the National Cancer Institute. Read more about  
Dr. Redmond on page 23.
Harder Family Endowed Chair in Cancer Research 
bestowed on Bernard A. Fox, Ph.D.
On March 5, 2015, family, friends, colleagues and supporters 
joined Dr. Bernard Fox in Palm Desert, Calif., for a celebratory 
reception in recognition of his contributions to immunotherapy 
and global efforts to cure cancer. Presented with the Harder Family 
Endowed Chair in Cancer Research by the Providence Portland 
Medical Foundation, Dr. Fox received messages of support and 
congratulation, including the following selected remarks: 
“I’ve known Bernie and supported his research efforts for  
20 years. He’s been a key to the growth of the Earle A. Chiles 
Research Institute. He’s made me and the Chiles Foundation 
proud. And the most exciting part of all this is the fact that he  
has so much more to offer us all. As the holder of the Harder 
Chair, he will continue with new discoveries. He will continue to 
publish his findings. He will continue on the path to cure cancer.”  
- Earle M. Chiles & The Chiles Foundation
 “Bernie is a world-recognized scientist who is frequently called 
upon by granting agencies, such as the NIH and FDA, academic 
institutions, biotechnology and pharmaceutical companies to 
provide expert opinion and serve as a subject matter expert in the 
immunotherapy of cancer.” – Raj K. Puri, M.D., Ph.D., director, 
Division of Cellular and Gene Therapies, Center for Biologics 
Evaluation and Research, U.S. Food & Drug Administration
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“Thank you, Bernie, for leading me and others along the path to 
finding a cure for cancer. Congratulations to you as you receive 
this prestigious honor.” – Tara Withington, executive director, 
Society for Immunotherapy of Cancer. 
“Your vision of cancer immunology and immunotherapy, and your 
passion and tireless efforts at realizing its success in our lifetime 
(who would have ever thought we would witness it from our days 
together at the NCI so many years ago!), will forever set apart  
the Earle A. Chiles Research Institute as one of the leaders in  
our field.” – James J. Mulé, Ph.D., associate center director for  
Translational Science, Moffitt Cancer Center. 
Learn more about Dr. Fox on page 16.
Your vision of cancer immunology and immunotherapy, and your passion 
and tireless efforts at realizing its success in our lifetime...will forever set 
apart the Earle A. Chiles Research Institute as one of the leaders  
in our field.
Steve Smith, a clinical trial patient of  
Dr. Todd Crocenzi, stays at Providence 
Guest House when receiving treatment. 
Located within walking distance to  
Providence Cancer Center, Providence 
Guest House opened in August 2015 
through generous philanthropic support  
for out-of-town patients and families.
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Steve Smith had few options for surviving stage IV colon 
cancer, but he entered a Phase I trial at Providence  
Cancer Center and gained a new lease on life.
Steve Smith, 63, sits by the fire in the main floor of Providence 
Guest House after flying in from Montana the night before and 
receiving his infusions of varlilumab and nivolumab that morning. 
He quips, “I already had an expiration date.”
It’s an amusing joke for the 29-year career salesman in grocery 
products for Proctor & Gamble. He’s in a good mood and  
explains why.
In February 2014, shortly after retiring and moving with his wife 
back to his boyhood home in Great Falls, Smith was diagnosed 
with stage IV colon cancer with liver metastases. He underwent 
chemotherapy for a year, a colectomy, seven tumor resections and 
removal of 24 lymph nodes. His cancer was stable for six months 
and then progressed.
With limited options in Montana, Smith and his oncologist began 
searching the Web and determined an immunotherapy trial 
offered the best hope. They found clinical trials that looked  
promising in Seattle, Phoenix and Minneapolis, among other 
cities, but decided on Portland because of the pioneering work 
performed at Providence Cancer Center and for its proximity  
to Vancouver, Wash., where Smith lived for much of his  
working career.
Screening Period
In April 2015, Smith visited Providence Cancer Center for a  
consultation with Todd S. Crocenzi, M.D., to see if he qualified for  
a Phase I/II trial combining 
two immunotherapy agents, 
varlilumab and nivolumab, 
in patients with advanced 
cancers. The screening 
included urine testing,  
electrocardiogram,  
chest X-ray, tumor biopsy, 
CT scans of his chest, 
abdomen and pelvis,  
and brain and blood draws 
to verify the absence of 
complicating factors.
A screen for biomarkers 
such as the non-mutated 
KRAS gene provided data  
to help investigators  
determine whether Smith 
might respond to the drugs.
“Fortunately for me, I met 
the requirements. As a 
cancer patient, you have to 
investigate what’s out there or miss an opportunity,” he says.
When Smith enrolled in the trial, he was among a small cohort of 
patients who have received a mid-range dose of medication. By 
2020, the target end date of the trial, approximately 190 patients 
are expected to be enrolled at up to 15 sites in the country. This is 
the first time varlilumab and nivolumab have been tested together 
in humans.
A PATIENT’S JOURNEY
Dr. Todd Crocenzi, right, and his patient, Steve Smith, review Smith’s 
CT scan showing tumor regression in response to the combination 
varlilumab and nivolumab Phase I/II clinical trial. 
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Home Away From Home
While the costs of the drugs are covered for Smith, he figures he’d 
spend about $30,000 on travel. Early on, no stranger to a lot of 
miles on the road in his job, Smith didn’t mind driving himself to 
his infusions every two weeks – a 700 mile trip. He says he used 
the time to turn on the music and let it all go. “Once I started to 
feel the results, a lot of my anxiety was taken care of,” he says.
Being able to stay at the Providence Guest House close to the 
hospital has made a huge difference to Smith. He doesn’t feel  
as transient as he did hopping around from one budget hotel to 
another like he and his wife did earlier in the trial. He uses some 
of his free time seeing a brother who lives in Vancouver.
“We are very pleased that we could offer Mr. Smith a therapeutic 
trial that was not available in his home state, and that he has 
shown a positive response to treatment. We are also grateful that 
he and his family are able to stay at the Providence Guest House 
during his treatment,” says Dr. Crocenzi.
Results
At the end of June 2015, two months after his screening visit, a 
CAT scan showed a 30 percent reduction in Smith’s tumors; by 
August, 43 percent; October, 60 percent; December, 75 percent; 
and at the end February 2016, Smith’s tumors had reduced by  
84 percent.
“I could be totally clear,” Smith says. “I’m not the only one who’s 
shaking his head.”
While reading the long list of possible side effects was intimidating, 
Smith shrugs off what he has experienced as mild – irritability at the 
site of his chest infusion port, joint pain and diarrhea. “You work it 
out when it’s all compared to staying alive,” he says.
Also, there has been the improvement in his quality of life. Smith 
has been enjoying spending time with his family, which includes 
nine grandchildren and 12 great-grandchildren. Among hobbies 
he’s taken up is panning for gold.
“I’m healthy enough to enjoy retirement,” he says.
Feature courtesy of Providence inScope. 
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R. Bryan Bell, M.D., 
D.D.S., FACS
Assistant member and medical director, 
Providence Oral, Head & Neck Cancer  
Program and Clinic
Head and Neck Oncologic Surgery
Dr. Bell’s research interest is in the characterization and 
manipulation of the tumor microenvironment in head  
and neck cancer. He seeks to develop novel clinical trials  
and treatment strategies to stimulate pre-surgical immune  
responses in patients with head and neck squamous  
cell carcinoma. 
Since joining Providence Cancer Center in 2010, Dr. Bryan Bell 
has been instrumental in expanding clinical research for patients 
with oral, head and neck cancer. Working closely with Rom S. 
Leidner, M.D., the portfolio of clinical trials has grown from one 
cooperative group trial in 2010 to more than 25 investigator- 
initiated, industry-funded and cooperative group trials in 2015. 
Dr. Bell serves as the principal investigator on a Phase Ib  
investigator-initiated trial of anti-OX40 prior to surgical resection, 
as well as an industry-sponsored Phase II trial of IRX-2, which 
contains interleukin-2 and various cytokines, administered at 
pre- and post-surgical resection. Nationally, Dr. Bell is among the 
highest accruing surgeons in a Phase II cooperative group trial 
(ECOG 3311) investigating transoral robotic surgery in head  
and neck squamous cell carcinoma (HNSCC). In August 2015, 
Drs. Bell and Leidner hosted the inaugural New Horizons in 
Immunotherapy for Head and Neck Cancer Symposium held  
in Newberg, Ore., bringing together leading investigators in  
HNSCC immunotherapy. 
In collaboration with the Integrated Therapies Laboratory led by 
Marka R. Crittenden, M.D., Ph.D., and Michael J. Gough, Ph.D., 
Dr. Bell seeks to develop a perioperative immunotherapy strategy 
to clear residual cancer cells in the surgical site without impacting 
normal tissues, anatomic structures or wound healing. “Such  
an intervention may also increase the number of patients eligible  
for surgical resection, since patients whose tumors have invaded 
critical structures may become eligible for surgery if we are able 
to eliminate remaining cancer cells,” says Dr. Bell. 
Dr. Bell has also engaged in a next generation immunoprofiling 
collaboration with Bernard A. Fox, Ph.D., whose laboratory  
has established a head and neck cancer tumor bank and  
cryopreserved more than 250 tissue samples from Dr. Bell’s 
patients. Multispectral imaging analyses of tumors from a cohort 
of patients with HNSCC has resulted in the development of a 
potential prognostic biomarker for oral cancer that may be  
used in the future to direct conventional treatment as well as 
immunotherapy. 
Another intramural collaboration includes Dr. Bell’s partnership 
with Andrew D. Weinberg, Ph.D., to examine the expression  
of immune modulatory proteins, OX40, PD-1, and CTLA-4, in 
HNSCC and to see whether these proteins could be targeted 
alone or in combination for future clinical trials. Further studies 
are centered on evaluating the primary tumor, metastatic  
and non-metastatic draining lymph nodes to identify novel 
immunotherapy targets, biomarkers of response, and how  
to best use immunotherapy combinations with the goal of 
translating their findings into innovative clinical trials. 
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Carlo B. Bifulco, M.D.
Member and director, Translational  
Molecular Pathology and Informatics
Anatomic and Molecular Pathology
As a pathologist with subspecialty  
training and expertise in molecular  
genetic pathology and hemato-pathology, Dr. Bifulco  
serves as director of the Molecular Pathology Core at  
the Earle A. Chiles Research Institute. He also serves as 
co-leader of the Biospecimen Core for the Pacific Cancer 
Research Consortium, a community site of the NCI  
Community Oncology Research Program. 
“Medicine is undergoing a major shift toward personalized 
health care, a model in which preventive and therapeutic  
practices are custom designed for each patient’s specific needs,” 
says Dr. Carlo Bifulco. “For cancer, personalized treatment is 
made possible by rapid and dramatic advances in DNA sequencing, 
which enables us to decode tumor genomes, and by new drugs 
that selectively target cells with damaged or mutated genes. 
These developments allow us to match drugs to patients with 
specific tumors, resulting in better outcomes, less toxicity and 
lower costs.”
The Molecular Pathology Core plays an important role in  
detecting tumor-driver mutations and tumor pathways that  
will respond well to certain drugs. It performs or coordinates 
tests for several molecular targets in multiple tumor types,  
including breast, colon, lung and hematologic malignancies.  
Test results are routinely incorporated into diagnostic pathology 
reports. “Now we’re preparing for the next leap forward in 
personalized care,” says Dr. Bifulco. “We’re transitioning from 
single gene mutation testing – that is, focusing on one gene  
at a time for specific targetable mutations – to mapping and 
decoding whole genomes. By comparing the patient’s normal 
DNA to the tumor DNA, we can identify all the potentially  
actionable mutations. This allows for more targeted,  
personalized treatment.”
At Providence Cancer Center, this process will be developed  
in stages through a multiphase approach. “First we’ll focus on 
characterizing cancers through next-generation sequencing of 
gene groups currently associated with specific tumor types.  
Later, as the technology and data interpretation become  
standardized and increasingly robust, we’ll extend this approach 
to the whole exome – the part of the genome most frequently 
altered in tumor-driving mutations. The ultimate goal is complete 
genetic profiling of tumors with the sequencing of whole tumor 
genomes,” says Dr. Bifulco.
This shift in cancer diagnostics and treatment approach will 
result in better and more affordable diagnostics and, most 
importantly, in improved clinical outcomes. Because there is an 
important role for personalized immunotherapy to complement 
the advancements in medical genomics and bioinformatics,  
Dr. Bifulco’s team is developing tests to characterize a patient’s 
immune response to a tumor. “We’re hopeful that this  
immunoprofiling approach will allow for further personalized  
use of immunotherapeutic agents in cancer treatment.”
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Alison K. Conlin, M.D., 
MPH
Associate member and medical director,  
Providence Breast Cancer Program  
and High-Risk Breast Clinic
Medical Oncology 
As a medical oncologist with training in population health 
and health outcomes, Dr. Conlin specializes in breast cancer 
clinical research as well as breast cancer risk evaluation, 
screening, and clinical and lifestyle interventions. 
Since her arrival at Providence Cancer Center in 2008, Dr. Alison 
Conlin has been an active clinical investigator. She serves as a 
member of the Alliance for Breast Cancer Committee. She is a 
member of the Southwest Oncology Group Breast Committee 
and Breast Cancer Working Group, in which she founded and 
co-chairs the Brain Metastasis Working Group. 
“Currently, I am on the advisory board of the Providence Breast 
Health Registry – a database of patients’ screening, diagnostic, 
treatment, and follow-up information,” says Dr. Conlin.  
“Additionally, I am the medical director of our high-risk breast 
clinic where we evaluate women for their breast cancer risk  
and counsel them to consider medications to reduce risk, such  
as tamoxifen, raloxifene, or exemestane, appropriate screening 
and testing practices, and lifestyle modifications that may  
reduce risk of future breast cancer.”    
In late 2014, Dr. Conlin became the co-principal investigator for 
the Providence Portland Medical Center site of the Pacific Cancer 
Research Consortium (PCRC), a community site of the NCI 
Community Oncology Research Program (NCORP). Comprising 
three major community cancer centers in the Western United 
States, PCRC includes Swedish Cancer Institute in Seattle,  
Mountain States Tumor Institute in Boise, and Providence  
Portland Medical Center, home to Providence Cancer Center  
and the Earle A. Chiles Research Institute. Along with their 
sub-components and 27 other participating components across 
Alaska, Washington, Oregon, Idaho, and California, PCRC-
NCORP is a consortium of 48 sites designed to conduct multi-site 
cancer clinical trials and cancer care delivery research through a 
5-year grant award from the NCI. 
Dr. Conlin is the leader of the PCRC Research Base Core which 
oversees the selection of PCRC cooperative group trials and 
represents PCRC to the National Clinical Trials Network Research 
Base. “The function of the PCRC Research Base Core is to ensure 
that we screen and select appropriate protocols for our PCRC 
sites and that we achieve accrual requirements,” says Dr. Conlin. 
“This is done through engaging and capitalizing on our  
investigators’ disease-specific expertise to review and select 
clinical trials from the participating research base portfolios.” 
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Marka R. Crittenden, M.D., 
Ph.D.
Assistant member, Integrated Therapies 
Laboratory
Director, Translational Radiation Research
Radiation Oncology
As a physician scientist trained in both radiation oncology 
and immunology, Dr. Marka Crittenden has a strong interest 
in the development of immunotherapy approaches for the 
treatment of cancer. 
“In my role as director of Translational Radiation Research, I am 
involved in multiple investigator-initiated Phase I and Phase II 
clinical studies combining immunotherapy with radiation therapy 
in melanoma, breast cancer, pancreatic and prostate cancer,” 
says Dr. Marka Crittenden. “I also co-lead with Michael J. 
Gough, Ph.D., the Integrated Therapies Laboratory which  
studies the integration of immunotherapy approaches targeting 
the immune environment within the tumor and conventional 
therapies such as chemotherapy and radiation.” Learn more 
about the Integrated Therapies Laboratory on page 18. 
In 2015, Dr. Crittenden contributed to numerous publications 
with intramural and extramural collaborators. She co-authored 
six journal articles and seven abstracts, including a first author 
publication entitled Current Clinical Trials Testing Combinations 
of Immunotherapy and Radiation (Semin Radiat Oncol. 
2015;25(1):54). At the 2015 annual meeting of the American 
Society of Clinical Oncology, she gave poster presentations on  
a Phase I/II study of stereotactic body radiation therapy in  
combination with a monoclonal antibody to OX40 in patients 
with metastatic breast cancer and a Phase I study of safety and  
immunogenicity of a Listeria monocytogenes vaccine, ADU-623, 
in patients with WHO grade III/IV astrocytomas. She served as 
institutional principal investigator on clinical trials for patients 
with glioblastoma and other tumor types, including a first-in- 
human study of a monoclonal antibody to PD-1 administered 
alone and in combination with other anti-cancer therapies in 
patients with advanced malignancies. 
Additionally, Dr. Crittenden served as an expert discussant for the 
Immunotherapy and Radiation Therapy session of the American 
Society of Therapeutic Radiation Oncology 2015 annual meeting 
in San Antonio, and co-chair of the Immune Therapy and Immune 
Modulation Workshop at the NRG Oncology Semi-Annual Meeting 
in Denver. She attended the 2015 annual meeting of the  
American College of Radiation Oncology in Washington, D.C., 
where she presented on “Radiation and Immunotherapy: A 
Primer,” as well as the 2015 annual meeting of the Radiation 
Research Society in Weston, Fla., where she presented on  
myeloid response to radiation therapy. Dr. Crittenden was also 
an active participant in the Radiation and Immune Modulation 
Working Group and Lung Cancer Working Group of the  
National Cancer Institute and engaged in collaborations with  
UC Davis, Sanford Health and Baylor College of Medicine.
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Todd S. Crocenzi, M.D.
Associate member and director,  
Gastrointestinal Oncology Research
Medical Oncology
As a medical oncologist with a strong 
interest in the immunologic aspects of  
cancer biology, Dr. Crocenzi’s ongoing 
professional goal is to develop methods of redirecting  
the immune system as a cancer therapeutic. 
As an oncology fellow at Dartmouth Hitchcock Medical Center, 
Dr. Todd Crocenzi was mentored by Marc Ernstoff, M.D., in the 
clinical care of patients with advanced melanoma and renal cell 
carcinoma undergoing standard and investigational immunotherapy 
regimens. He also gained experience in translational research 
and was a co-principal investigator on an institutional grant 
which funded a clinical trial of a novel dendritic cell vaccine  
for metastatic melanoma and renal cell carcinoma. It was this 
training and experience in investigational immunotherapy which 
led to Dr. Crocenzi’s directorship of Gastrointestinal Oncology 
Research at the Earle A. Chiles Research Institute, where he 
seeks to improve immunotherapeutics for patients with  
gastrointestinal cancers. 
“As a physician scientist developing novel cancer therapy, I believe 
immunotherapy can integrate with current conventional  
therapies to optimize effectiveness. To this end, I designed  
and conducted two clinical trials evaluating the safety and  
feasibility of chemo-immuno-radiotherapy in patients with locally 
advanced or borderline resectable pancreatic cancer. I continue 
to work with Michael J. Gough, Ph.D., and Marka R. Crittenden, 
M.D., Ph.D, to analyze blood and tissue samples from these 
patients to formulate other translational research projects in 
pancreatic, liver and colorectal cancer,” says Dr. Crocenzi. 
Dr. Crocenzi has collaborated with Duke University on a  
multi-institutional clinical trial to explore a multi-peptide, viral 
vector delivered vaccine in patients with resected, metastatic 
colorectal cancer. Most recently, Dr. Crocenzi collaborated with 
Dung Le, M.D., of Johns Hopkins University in the clinical trial 
demonstrating the efficacy of PD-1 inhibition in patients with 
metastatic colorectal cancer and mismatch repair deficiency (N Engl 
J Med. 2015; 372(26):2509). “Dr. Le and I were also awarded a 
PANCAN-AACR Research Acceleration Network Grant, a  
$1 million award to support our ongoing clinical trial exploring  
a prime-boost vaccination strategy in combination with  
anti-PD-1 antibody for second line treatment of metastatic  
pancreatic adenocarcinoma,” says Dr. Crocenzi. 
Dr. Crocenzi is an active investigator on several other  
investigator-initiated clinical trials combining immunotherapy, 
chemotherapy and radiation therapy as well as multi-center 
studies through the Cancer Immunotherapy Trials Network  
and the cooperative group system of the NCI.
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Brendan D. Curti, M.D.
Member and director, Genitourinary  
Oncology Research
Director, Cytokine and Adoptive  
Immunotherapy Program
Co-director, Providence Melanoma  
Program 
Medical Oncology
Dr. Curti is a principle investigator on numerous translational 
clinical trials and a recognized leader in melanoma,  
genitourinary and interleukin-2 (IL-2) immunotherapy. 
Dr. Brendan Curti served as the principal investigator on the first- 
in-human OX40 study that was performed at Providence Cancer 
Center. Based on the promising results of the Phase 1 trial, new 
OX40 agonists and combinations are being investigated in the clinic 
in conjunction with collaborators at MedImmune, which acquired 
the rights to develop OX40 agonists. This includes several in-house 
studies testing the immunological effects in the tumor specimens of 
pre-operative administration of anti-OX40 in patients with advanced 
oral, head and neck cancer, and in patients with liver metastases 
from colorectal cancer.
Intratumoral therapy for melanoma has been a longstanding clinical 
research interest of Dr. Curti’s. Providence Cancer Center enrolled 
the first patient on the Phase III talimogene laherparepvec trial that 
was the basis for its FDA approval (J Clin Oncol 2015, 33(25):2780). 
Dr. Curti is an active collaborator on clinical research studies investi-
gating another oncolytic virus, CAVATAK (Coxsackie Virus CVA-21). 
Presentations of this research were given at the 2015 annual  
meetings of the American Society of Clinical Oncology and  
American Association for Cancer Research. “Based on pre-clinical  
data showing synergy with anti-CTLA-4, I authored a clinical trial  
studying the combination of CAVATAK and ipilimumab in patients  
with advanced melanoma and a subcutaneous melanoma deposit 
suitable for intratumoral vaccination,” says Dr. Curti. Four of the first  
five patients have achieved a partial regression of disease. Detailed 
analysis of immune parameters including immunoscore is being  
performed. Collaborators include the John Wayne Cancer Institute  
and the Huntsman Cancer Institute. 
Galectins are proteins with immune suppressive properties produced  
in excess by many malignancies. William L. Redmond, Ph.D., studied 
galectin inhibitors in conjunction with T-cell costimulatory antibodies  
and demonstrated enhanced anti-tumor activity in pre-clinical tumor 
models. To translate this work to the clinical setting, Dr. Curti authored 
two clinical trials, one combining the galectin inhibitor, GR-MD-02,  
with the anti-CTLA-4 agent, ipilimumab, and another combining it  
with the anti-PD-1 agent, pembrolizumab. Both are first-in-human 
studies conducted at Providence Cancer Center. An R21 NIH grant  
award for immune monitoring on these trials was funded in 2015. 
Dr. Curti’s investigations of stereotactic body radiation therapy (SBRT) 
plus IL-2 in collaboration with Marka R. Crittenden, M.D., Ph.D., are 
ongoing. The randomized Phase II study in melanoma, which opened  
in 2012, is nearing completion. The results are still preliminary;  
however, the probability of objective response in patients who  
received SBRT plus IL-2 was 30 percent and those receiving  
IL-2 monotherapy was approximately 15 percent. Another randomized 
Phase II comparison of SBRT plus IL-2 and IL-2 began enrolling in 2015  
in patients with advanced renal cancer. A biomarker study of the  
immunomodulatory effects of IL-2 in these patients was published 
(Immunity 2015, 43(2):240). Other Cytokine Working Group members 
will become collaborators on the SBRT plus IL-2  trial in renal cancer  
in 2016. 
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Bernard A. Fox, Ph.D.
Member, Molecular and Tumor  
Immunology Laboratory
Harder Family Endowed Chair in  
Cancer Research
Dr. Fox and his laboratory seek to  
improve the effectiveness of cancer  
immunotherapy. This includes a preclinical effort to develop 
strategies to increase efficacy and a clinical effort to translate 
these findings into clinical trials for patients with cancer. 
“My lab is interested in assessing the immune infiltrate that 
exists within the tumor microenvironment, also known as  
immunoscore, and how we might increase the number and 
augment the function of immune cells in that environment 
through various immunotherapeutic strategies. Patients with a 
positive immunoscore have fared well on checkpoint inhibitors 
such as anti-PD-1, but patients with a negative immunoscore 
require other immunotherapeutic modalities to increase their 
immunoscore, and this is a major focus of my research,”  
says Dr. Bernard Fox. The immunoscore research by the Fox  
Laboratory has led to a biotechnology collaboration with  
PerkinElmer enabling the use of multispectral imaging to  
assess five to eight markers on a single tumor section. This has 
allowed a greater understanding of cell types, functionality,  
and cell-to-cell interactions within the tumor microenvironment.  
This work was performed with samples from both pre-clinical 
models and samples from clinical trials, and was presented at  
the American Association of Immunologists and the Society for 
Immunotherapy of Cancer (SITC) 2015 annual meetings. 
The future of immuno-oncology lies in combination immuno-
therapies, and Dr. Fox’s laboratory is studying the impact of 
combining various reagents to improve anti-tumor efficacy.  
“We have found that the sequence of how antibodies for OX40 
and PD-1 are administered is important in determining whether 
combination treatment is effective,” says Dr. Fox. “We have 
partnered with a major pharmaceutical company to examine 
novel reagents targeting immune function, and our research  
was cited as part of the technical brochure for FDA approval of 
the first-in-human clinical trial of anti-VISTA. Our hope is that 
this combination approach will lead to more effective cancer 
therapies for patients.” 
An additional focus of the laboratory is assessing antibody 
responses both as an effector function as well as surrogates of  
T-cell immunity in both human and murine systems. “Previously, 
we observed in a clinical trial of combination immunotherapy for 
men with advanced prostate cancer, those who had increased 
PSA doubling time had increased number of strong antibody 
responses to antigens on circulating tumor cells,” says Dr. Fox. 
“We extended this research in a pre-clinical model demonstrating 
that our autophagosome vaccine, DRibbles, plus poly-IC  
produced antibody responses against antigens within the  
vaccine.” This work was also presented at the 2015 SITC annual 
meeting, where Dr. Fox was honored with a SITC Visionary / 
Legacy Award in recognition of his ingenuity and steadfast 
commitment to advancing cancer immunotherapy. Earlier in  
the year, Dr. Fox was awarded The Harder Family Endowed  
Chair in Cancer Research by the Providence Portland Medical 
Foundation in honor of his distinguished record of leadership 
and scientific contributions (see page 6). 
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John E. Godwin, M.D., 
MS
Member and program leader,  
Hematologic Malignancies
Medical Oncology
Dr. Godwin’s research interest is in clinical 
immunotherapy of hematologic malignancies, also known 
as blood cancers. This entails understanding the various 
mechanisms of immune resistance and suppression in  
hematologic malignancies. 
Through intramural and extramural collaborations, Dr. John Godwin 
seeks a greater understanding of immune system functionality in 
hematologic malignancies for the development of more effective 
cancer therapeutics. In 2015, Dr. Godwin’s activities were devoted 
to several areas of hematological research. “Firstly, I have brought 
about unique investigator-initiated studies,” says Dr. Godwin.  
One is a tissue collection protocol for bone marrow samples in  
Myelodysplastic Syndromes (MDS) patients, specifically evaluating 
the presence of myeloid derived suppressor cells in MDS. 
“Secondly, we have enhanced our clinical trial portfolio by opening 
several novel immunotherapy trials in hematologic malignancies,” 
says Dr. Godwin. These include the chimeric antigen receptor (CAR)  
T cell therapy from Kite Pharma for mantle cell Non-Hodgkin  
Lymphoma (NHL) and the bispecific antibody therapy for Acute  
Myeloid Leukemia (AML), MGD006. A trial investigating the  
anti-CD30 immunoconjugate in combination with anti-PD-1 
(nivolumab) through Bristol-Myers Squibb and Seattle Genetics  
has also been opened, and activation of a trial of the anti-CD33 
immunoconjugate from Seattle Genetics, SGN33, for AML and 
MDS is in process. “We are one of only a few sites in the country 
working with Kite CAR T cells and the MGD bispecific antibody,” 
says Dr. Godwin. 
Additionally, Dr. Godwin is responsible for the continued  
development of the hematologic malignancies program in the 
Providence Oregon Region. “We have an active tumor board that 
has increased presentations, and our enrollment in clinical trials in 
hematologic malignancies has increased in the past year,” says  
Dr. Godwin. In 2015, Providence Health & Services established a 
system-wide Clinical Program Group focused on hematologic 
malignancies, of which Dr. Godwin is a co-leader. Through this 
group, Dr. Godwin has been active in establishing a system-wide 
pathology report which includes specific tumor markers in NHL.
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Michael J. Gough, Ph.D.
Assistant member, Integrated Therapies 
Laboratory
The Integrated Therapies Laboratory is  
a collaborative research effort between 
Michael J. Gough, Ph.D., and Marka R. 
Crittenden, M.D., Ph.D. It encompasses 
their overlapping research interest into the ability of  
cytotoxic therapy to provide large-scale cancer cell death  
in vivo, while modifying the immune cell profile within  
the tumor.
“This year was an important year for the  
laboratory,” says Dr. Michael Gough.  
“Firstly, we expanded. We acquired a second 
post-doctoral fellow and two additional  
research associates in 2015. Secondly, our 
projects based around the STING sensor have 
matured. We have successfully published our 
first paper on this topic in Cancer Research, 
which also resulted in an image of ours being selected  
as cover art for the January 2016 issue,” says Dr. Gough  
(Cancer Res. 2016 Jan 1;76(1):50. Epub 2015 Nov 13).
Subsequent manuscripts are in progress and three grant awards 
to continue investigation of the STING sensor were received:  
a postdoctoral fellowship from the American Cancer Society;  
an award from the Oral Maxillofacial Surgery Foundation with  
R. Bryan Bell, M.D., D.D.S., to initiate a preclinical surgical model; 
and an award from the Heath Foundation to apply findings to 
pre-malignant disease. 
A collaboration with Victor DeFilippis, Ph.D., at the Vaccine and 
Gene Therapy Institute to investigate a collection of novel small 
molecule STING ligands is underway. The laboratory’s collaboration 
with Jacob Raber, Ph.D., at Oregon Health & Science University 
has continued to earn grant awards, most recently resulting in a 
prestigious Howard Hughes Medical Institute Medical Research 
Fellows Award for a second-year medical student under  
Dr. Gough’s mentorship.
The laboratory has developed a strong pipeline of new areas  
of investigation. Much interest has been shown in its project  
investigating the role of macrophage phagocytic receptors in  
the response to radiation therapy. Manuscripts describing one 
candidate pathway and findings from the laboratory’s first  
clinical trial testing pancreatic cancer patients are in development.
National recognition has brought Dr. Gough invitations to speak 
at medical, scientific and industry conferences and meetings. 
Presentations were given at Thomas Jefferson University, Rigel 
Pharmaceuticals, Bristol Meyers-Squibb, and New Horizons in 
Immunotherapy for Head and Neck Cancer Symposium with 
additional presentations at universities and conferences planned 
in 2016. See page 13 to learn about Dr. Crittenden’s activities. 
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Hong-Ming Hu, Ph.D.
Associate member, Cancer  
Immunobiology Laboratory
The long-term goal of the Cancer  
Immunobiology Laboratory is to  
understand how the immune system 
senses tumor cells and to develop effective 
cancer vaccines and other immunotherapy strategies.
Dr. Hong-Ming Hu leads the Cancer Immunobiology Laboratory  
in productive, innovative research with a special interest in  
the development of therapeutic cancer vaccines. He is both  
knowledgeable and well versed in molecular and cellular  
immunology studies and is directly involved in the clinical  
translation of ideas and concepts that originate from his  
laboratory. “My laboratory investigates how tumor cells,  
live or dead, are sensed by the immune system. A better  
understanding of how the immune system recognizes tumor 
cells will lead to the design of more effective cancer vaccines  
and immunotherapy strategies,” says Dr. Hu.
Dr. Hu’s interest in autophagy, the mechanism by which cells 
dispose of unnecessary or dysfunctional components, and its  
role in regulating antitumor immune responses has spawned 
several areas of investigation. “Our research in antigen cross- 
presentation led to an original finding that cross-presentation of 
tumor-associated antigen is regulated by autophagy in tumor 
cells. We have also made several new discoveries that uncover 
the mechanisms by which autophagy regulates the efficiency  
of cross-presentation and antitumor immune responses,” says 
Dr. Hu. “Based on these exciting discoveries, we seek to develop 
a deeper understanding and clearer picture of how autophagy 
regulates antitumor immune response.”  
Another major focus of Dr. Hu’s laboratory is the research and  
development of DRibble vaccines, a novel therapeutic cancer 
vaccine platform based on tumor-derived autophagosomes  
developed in collaboration with Bernard A. Fox, Ph.D. DRibbles 
have been shown to induce a strong tumor-specific immune 
response and mediate tumor regression in several tumor models. 
Using pre-clinical models of breast and lung cancer, Dr. Hu’s 
laboratory has determined that the effect of a combination of 
agonist antibodies against T-cell costimulatory molecules (OX40, 
CD27, GITR) and/or immune checkpoint blockade (PD-1 or 
PD-L1) could boost T-cell mediated immune responses induced  
by vaccination with DRibbles. “We generated preliminary data 
showing such combinations are therapeutically more effective 
than either vaccine or antibody alone,” says Dr. Hu. “Ongoing 
experiments are underway to determine the antitumor effects 
and mechanisms of these combinations. Results from these 
studies could form the basis for multiple clinical trials.”
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Rom S. Leidner, M.D.
Assistant member and co-director,  
Providence Oral, Head and Neck  
Cancer Program
Medical Oncology
Dr. Leidner has pioneered the expansion 
of immunotherapy in head and neck 
cancer, applying knowledge gained from lung cancer and 
melanoma studies to patients with head and neck cancer.
The success of immunotherapy in melanoma has inspired many 
researchers to test the impact of boosting the immune system 
against other cancer types. As a physician scientist with an 
interest in head and neck cancer, Dr. Rom Leidner has been at 
the leading edge of applying various immunotherapy agents to 
head and neck cancer patients, including immune checkpoint 
inhibitors, combination therapies, and adoptive transfer of tumor 
infiltrating lymphocytes (TIL). Through philanthropic support 
from Providence Portland Medical Foundation, Dr. Leidner  
treated the first oral squamous cell carcinoma (SCC) patient with 
adoptive TIL plus tumor-derived, autophagosome-enriched 
DRibbles vaccine (DPV-001). His group was the first to enroll  
SCC patients in trials of both pre-operative murine OX40 agonist 
(MEDI6469) and pre-operative anti-PD-L1 (durvalumab). “We  
ran the first-in-human Phase I trial of a humanized monoclonal 
OX40 agonist antibody, MEDI0562, in patients with head and 
neck squamous cell carcinoma,” says Dr. Leidner. “We are at  
the national forefront in this capability.”
Dr. Leidner authored and presented five abstracts at international 
meetings and co-authored two articles in 2015, including a 
publication with R. Bryan Bell, M.D., D.D.S., on effective  
immunotherapies in oral, head and neck cancer (J Oral Maxillofac 
Surg. 2015;73(12 Suppl):S107). Together with Dr. Bell, he  
organized the inaugural New Horizons in Immunotherapy for 
Head and Neck Cancer Symposium, bringing together leading 
investigators in the field of head and neck squamous cell  
carcinoma (HNSCC) immunotherapy.
An active member of the Providence Portland Medical Center 
Institutional Review Board, Dr. Leidner serves as the site principal 
investigator on 10 Phase I/II clinical trials, including a newly- 
opened investigator-initiated trial using liquid biopsy to analyze 
circulating tumor DNA in plasma from head and neck cancer 
patients. Another trial testing a human monoclonal anti-PD-1 
treatment for cutaneous SCC will begin recruiting patients in 
2016. Additional industry-sponsored studies are in development, 
testing intra-tumoral modeling directly at the level of cancer cells 
and TIL in HNSCC patients. 
Dr. Leidner values the collaborative environment of the Earle A. 
Chiles Research Institute. Through multiple intramural collaborations, 
he has helped build a database of more than 100 samples from 
HNSCC patients for the creation of autologous TIL and multiplex 
immunohistochemical analyses of immune infiltration in primary 
tumors. These tissue libraries have potential as future discovery 
platforms for adoptive transfer and aid in predicting patient 
responders. Ongoing intramural collaborations will focus on both 
human and pre-clinical studies of combination immunotherapies 
for head and neck cancer. Dr. Leidner hopes to expand his  
clinical research endeavors in glioblastoma, gastroesophageal, 
thyroid, salivary, and other rare tumors in the future.
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Philippa H. Newell, M.D.
Assistant member and medical director, 
Providence Liver Cancer Clinic
Liver and Pancreas Surgery
Dr. Newell is pursuing new combination 
therapies for patients with hepatocellular 
carcinoma, the most common type of 
primary liver cancer. By combining traditional liver-directed 
therapies with immunotherapy, she hopes to provide a 
wider range of effective treatment options for this  
patient population. 
Many patients with hepatocellular carcinoma (HCC) have  
underlying chronic liver disease and recurrence rates following 
standard treatment are high. Radiofrequency ablation (RFA) for 
HCC involves a specialized needle that is placed in the center  
of the tumor to destroy tumor cells with high temperature, also 
known as thermal ablation. By removing a small piece of the 
tumor from the needle, Dr. Philippa Newell can analyze the  
molecular pathways that are altered in response to RFA. She has 
found an increase in heat shock proteins, which mediate the 
cellular response to protein damage and are indicators of cellular 
stress. “The big challenge with these molecular approaches is 
teasing out the effects of the tumor, compared to the treatments, 
when the liver itself is also highly diseased,” says Dr. Newell.
Dr. Newell is principal investigator or co-principal investigator on 
multiple clinical trials. She co-authored and presented five posters 
at international research conferences in 2015 and was first 
author on the article Mulitmodal Treatment of Unresectable 
Hepatocellular Carcinoma to Achieve Complete Response  
Results in Improved Survival (HPB 2015, 17(5):454). 
Dr. Newell is investigating combinations of the immune  
checkpoint inhibitor anti-PD-1 plus stereotactic radiation and  
RFA in a Phase I/II safety and feasibility trial for HCC patients.  
She is also investigating the molecular pathways affected by these  
combinations in pre-clinical models of liver cancer with Marka R. 
Crittenden, M.D., Ph.D., and Michael J. Gough, Ph.D. Additionally, 
Dr. Newell has started a Phase I safety trial with Brendan D. Curti, 
M.D., testing pre-operative anti-OX40 immunotherapy plus RFA in 
patients with colorectal cancer that has metastasized to the liver. 
Dr. Newell’s clinical interests also include pancreatic cancer,  
with projects that focus on prognostic approaches to support 
informed clinical decision making for these patients. At the 2015 
annual meeting of the Society for Immunotherapy of Cancer,  
she described an analysis of circulating immune cells as potential 
biomarkers for malignancy of pancreatic tumors. She also gave 
an oral presentation at the North Pacific Surgical Association 
conference on results from a retrospective analysis of the use  
of pre-operative CT scans to predict the development of post- 
operative pancreatic fistula after pancreatectomy, accepted for 
publication in the American Journal of Surgery. With the recent 
push to use personalized medicine to predict which patients will 
benefit from specific therapies, she is collaborating with Rom S. 
Leidner, M.D., to perform whole-exome sequencing in patients 
with head and neck cancer and pancreatic adenocarcinoma. 
Community outreach and collaboration are important to  
Dr. Newell. She organizes a Portland city-wide HCC meeting that 
brings together specialists from multiple disciplines to discuss  
the latest updates on management of hepatocellular carcinoma. 
The conference includes providers from many different hospital 
systems and private clinics in Portland.
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David B. Page, M.D.
Assistant member, Breast Cancer  
Immunotherapy
Medical Oncology
As a newly-appointed faculty  
member, Dr. Page seeks to explore  
novel combination strategies, identify 
immune-based biomarkers of response, and develop  
cancer immunotherapies to improve outcomes for  
patients with breast cancer. 
Dr. David Page joined the Earle A. Chiles Research Institute in 
July 2015 after completing a medical oncology fellowship at 
Memorial Sloan Kettering Cancer Center. His research focuses  
on the clinical development of immunotherapy in breast cancer. 
Dr. Page serves the Portland breast cancer advocacy community 
as a clinician, researcher, and educator. He is a board member  
of the Breast Friends Foundation, Medical Advisory Committee 
member for the Ore. and SW Washington Chapter of the Susan 
G. Komen Foundation and a frequent peer-reviewer for grant 
agencies and academic journals.
“My primary research focus is to develop and implement clinical 
trials that evaluate novel combination strategies designed to 
overcome immunologic tolerance in breast cancer,” says  
Dr. Page. Since his arrival, Dr. Page has developed several  
investigator-initiated clinical trials for both early stage breast 
cancer and metastatic disease. These include a study combining 
cytotoxic chemotherapy with immunologic checkpoint blockade 
to characterize the immunologic effects of chemotherapy, a 
study to evaluate whether next-generation immune-based 
assays, such as T-cell receptor sequencing or RNA transcriptional 
profiling, can predict clinical response in early stage breast  
cancer, and studies evaluating pre-operative immunotherapy  
in early stage breast cancer. 
“My secondary focus is to develop novel immune-based  
biomarkers that may one day be used to guide treatment  
with immunotherapy,” says Dr. Page. “I have expertise in flow 
cytometry, seromics, and cytokine array platforms, as well as 
next-generation sequencing assays including Nanostring and 
T-cell clonal repertoire analysis.” Grant funding from the Terri 
Brodeur Breast Cancer Foundation supports Dr. Page’s research 
to evaluate clonal repertoire analysis as a novel predictive  
biomarker in the setting of neoadjuvant pertuzumab-based 
chemotherapy to facilitate disease control in women with brain 
metastases. A Carol Litwin Memorial Fellowship from the SASS 
Foundation supports his Phase Ib study of peri-operative  
cryo-immunotherapy and candidate immune-based predictive 
biomarkers to harness the curative potential of lymphocytes in 
women with early stage breast cancer.
In 2015, Dr. Page was honored with a Young Investigator Award 
from the American Society of Clinical Oncology, one of 58 award 
recipients worldwide, to investigate T-cell receptor DNA deep 
sequencing as a novel immune-based biomarker in early stage 
breast cancer. He also received a Clinical Research Excellence 
Award from the Immuno-Oncology Young Investigator’s Forum, 
a program of the Academic Research Coalition, and a Breast 
Symposium Merit Award from the Society for Immunotherapy  
of Cancer. 
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William L. Redmond, Ph.D.
Associate member, Cancer  
Immunotherapy Laboratory
Dr. Redmond and his laboratory seek  
to elucidate the mechanisms by which  
T cell co-stimulation through ligation of 
the TNF receptor family member OX40 
(CD134) boosts CD8 T cell survival, differentiation,  
and the efficacy of tumor immunotherapy. 
“We are exploring how specific combinations of immunotherapy 
agents can be used to boost the function of specialized white 
blood cells, known as killer T cells, which have the ability to  
detect and eliminate malignant cells,” says Dr. Redmond. “By 
understanding the mechanisms by which these drugs regulate 
tumor-specific immunity, we hope to develop more effective 
cancer therapeutics capable of harnessing the power of the 
immune system.” 
One area of active investigation is how combinatorial approaches 
to immunotherapy can synergize to increase anti-tumor immunity. 
These studies helped demonstrate how two different immune- 
boosting drugs, anti-OX40 antibody plus interleukin-2, could be 
combined to induce more robust tumor regression than either 
agent alone. Research conducted by Dr. Redmond’s laboratory  
has also revealed a unique synergy between OX40-specific  
immunotherapy and blockade of the immune checkpoint CTLA-4. 
“This approach was the equivalent of stepping on the gas pedal 
while taking your foot off the brakes,” said Dr. Redmond. 
Another major focus of the laboratory is investigating the  
mechanisms by which tumor-specific vaccines plus combination 
immunotherapy can revive killer T cells that had been suppressed 
by the tumor. “We are studying how dual anti-OX40/anti-CTLA-4 
therapy plus vaccination rescues killer T cells that have been shut 
down by progressively growing tumors so that they can be  
reactivated to destroy the cancer,” says Dr. Redmond. 
Key accomplishments in 2015 include receiving a Career Catalyst 
Research Grant from the Susan G. Komen Foundation and an R21 
grant award from the National Cancer Institute with Brendan D. 
Curti, M.D., to fund an on-going phase I clinical trial of Ipilimumab 
(anti-CTLA-4) plus a Galectin-3 inhibitor (GR-MD-02) in patients 
with metastatic melanoma. Additionally, there were three  
publications from Dr. Redmond’s team in 2015, highlighted by a 
forthcoming article in Proceedings of the National Academy of 
Sciences entitled Combination OX40 Agonism/CTLA-4 Blockade 
with HER2 Vaccination Reverses T-cell Anergy and Promotes 
Survival in Tumor-Bearing Mice. Four poster presentations were 
made by Redmond Laboratory postdoctoral fellows and research 
associates at the Society for Immunotherapy of Cancer 2015 
annual meeting.
FACTS &
FIGURES
NEW &  
NOTEWORTHY
FACULTY  
MEMBERS
CORE 
FACILITIES
FRANZ LEADERSHIP 
CABINET
A PATIENT’S  
JOURNEY
SELECT 
PUBLICATIONS
EVENTS & 
ENGAGEMENT
EDUCATION & 
TRAINING24
Rachel E. Sanborn, M.D.
Associate member, Phase I Clinical Trials 
Program
Co-director, Providence Thoracic 
Oncology Program
Medical Oncology
Dr. Sanborn’s research interests and clinical practice include 
clinical and translational research in thoracic oncology, and 
the development of new agents via the Phase I Clinical Trials 
Program at Providence Cancer Center. 
The primary focus of Dr. Rachel Sanborn’s clinical and translational 
research involves the investigation of immunotherapy or in 
combinations of immunotherapy agents with standard therapy. 
“This entails partnering with pharmaceutical companies in novel 
clinical trials, as well as partnering with other institutions across 
the country in the conduct of research,” says Dr. Sanborn.  
“This also includes collaborating with the immunologists at  
our institution investigating novel agents, such as the DRibble 
vaccine, in ongoing clinical trials, and in the active process of 
developing new clinical trials.”  
The Phase I Clinical Trials Program has expanded significantly 
over the past year, dramatically increasing the number of  
available Phase I clinical trials to more than 50 by year-end 2015. 
“The reputation of the Earle A. Chiles Research Institute as a 
referral center for early-phase and innovative research has  
grown commensurately, with a steady increase in referrals from  
across the region and out of state,” says Dr. Sanborn.  
Dr. Sanborn opened and initiated accrual to an investigator- 
sponsored Phase I/II trial of MK-3475 with gemcitabine in  
patients with previously-treated advanced non-small cell  
lung cancer. 
In 2015, Dr. Sanborn was elected by colleagues to serve as 
medical director for the Cancer Research and Biostatistics (CRAB) 
Clinical Trials Consortium Lung Cancer Research team. This  
is a four-year term, which will involve working with the  
multi-institution consortium in developing and expanding  
the clinical research portfolio and memberships.
Dr. Sanborn also served as a peer reviewer for grant applications 
for the Department of Defense Lung Cancer Research Program 
and as a panel member for the American Lung Association  
Take Action Network. She was co-chair of the American Lung  
Association’s Lung Force Expo held in Portland, Ore., where she 
presented on “Lung cancer screening:  Evidence, benefits, and 
pitfalls from a high-volume program’s perspective.” She also 
serves as a member of Free to Breathe’s Medical Advisory  
Workgroup, which consists of a panel of physicians focused  
on thoracic oncology nationally. 
Within Providence Health & Services, Dr. Sanborn is a member of 
the Thoracic Oncology Clinical Focus Group, and acts as co-chair 
for its thoracic medical oncology working group subcommittee. 
She is also a member of the Genomics Clinical Focus Group.
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Andrew D. Weinberg, 
Ph.D.
Member, Basic Immunology Laboratory
Dr. Weinberg and his laboratory focus on 
cellular and molecular mechanisms of 
action of OX40 agonists. OX40-based  
therapy leads to tumor regression in cancer-bearing  
mice, both as monotherapy or when combined with  
other immunotherapy modalities. Their pre-clinical research 
has shown that OX40-based therapy leads to tumor  
regression, both as monotherapy and when combined  
with other immunotherapy modalities.
The Basic Immunology Laboratory led by Dr. Andrew Weinberg 
uses pre-clinical models to study the molecular pathways involved 
in co-stimulation of T cells using agonist anti-OX40 antibodies. 
“Using an immunization model in the lab, we examined changes 
that occur in phospho-protein levels within antigen-stimulated  
T cells comparing anti-OX40 to the immune check-point inhibitor 
anti-CTLA-4. We found that anti-OX40 treatment led to  
increased T cell survival and production of memory T cells,” 
says Dr. Weinberg. In the MCA205 pre-clinical tumor model, 
anti-OX40 was found to bind to regulatory T cells (Tregs) from  
the tumor microenvironment. To characterize how OX40 agonists 
affect Treg function, gene array experiments were performed to 
analyze the molecular changes of Tregs from tumors treated with 
and without anti-OX40. “Several transcripts within tumor-isolated 
Tregs were consistently altered with OX40 agonists. We are  
currently confirming these changes on the protein level,” says  
Dr. Weinberg.
Dr. Weinberg is engaged in multiple preclinical and clinical  
intramural collaborations with the Providence Oral, Head and 
Neck Cancer Program, Breast Cancer Program, Radiation  
Oncology, and Cytokine and Adoptive Immunotherapy Program, 
as evident in his co-authorship of the review article OX40  
Signaling in Head and Neck Squamous Cell Carcinoma:  
Overcoming Immunosuppression in the Tumor Microenvironment 
(Oral Oncology. 2016;52:1; Epub 2015 Nov 21). Examinations  
by his laboratory of immune response to combination anti-OX40 
and TGFß receptor blockade resulted in a publication for which  
he was senior author (Cancer Immunol Res 2015, 3(5):526).
In recognition of his seminal contributions to the emerging field of 
T-cell agonist immunotherapy, Dr. Weinberg was selected to serve 
as a co-organizer for the Society for Immunotherapy of Cancer 
30th Anniversary Annual Meeting held in National Harbor, Md.  
He also served as co-chair for the meeting’s Coinhibition and 
Costimulation Session which focused on new costimulation 
(OX40) and coinhibition (VISTA) pathways of T cells, and  
combination therapy with anti-CTLA-4 and anti-PD-1.  
Dr. Weinberg also co-chaired the inaugural Cambridge Health 
Institute Agonist Immunotherapy Targets stream at the 11th 
Annual Protein Engineering Summit held in Boston. He served as a 
moderator of the Combinations in Cancer Immunotherapy Session 
and also presented on OX40 Agonist Combined with PD-1 and 
TGFß Receptor Blockade. Additional speaking invitations brought 
Dr. Weinberg to the 8th Annual Canadian Cancer Immunotherapy 
Consortium Symposium, the inaugural New Horizons in  
Immunotherapy for Head and Neck Cancer Symposium held in 
Newberg, Ore., and to South Korea for seminars given to the 
Korean Society for Immunology and Academy of Immunology  
and Microbiology. 
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Kristina H. Young, M.D., 
Ph.D.
Assistant member, Tumor  
Microenvironment Laboratory 
Radiation Oncology
Dr. Kristina Young joined the faculty of the 
Earle A. Chiles Research Institute to pursue translational 
cancer immunotherapy research with a focus on the tumor 
microenvironment and radiation oncology. 
Dr. Kristina Young’s research interests include the role of cancer- 
associated fibroblasts on immune-mediated radiation resistance in 
the treatment of pancreatic cancer. Her laboratory is investigating 
how inhibition of the fibroblast activation protein (FAP) combined 
with radiation can delay or impede tumor growth. “Thus far  
we have found that FAP inhibition with radiation results in two  
separate tumor growth delays in pre-clinical models. We observed 
an early delay approximately seven days following radiation  
therapy, and a second delay approximately three weeks following 
last therapy,” says Dr. Young. Additional experiments are planned 
to determine the mechanism of action and enhance these  
findings. The laboratory is also investigating the direct and  
indirect inhibition on radiation efficacy. “Based on our previously  
published data demonstrating enhanced radiation efficacy in 
pre-clinical models, we are performing further experiments to 
determine if the improved response to radiation was a direct  
effect of CD8 T cells,” says Dr. Young. 
Dr. Young is also an active clinical investigator. She is principal 
investigator of an investigator-initiated Phase II clinical trial 
testing TGFß inhibition in patients undergoing neoadjuvant 
chemoradiation for locally advanced rectal cancer, and is  
engaged in intramural collaborations with Todd S. Crocenzi, 
M.D., and Philippa H. Newell, M.D., on a multi-institution Phase I 
trial of stereotactic body radiation therapy (SBRT) plus nivolumab 
in patients with hepatocellular carcinoma not eligible for other 
liver-directed therapies. Additionally, her collaborations with  
Marka R. Crittenden, M.D., Ph.D., and Michael J. Gough, Ph.D., 
resulted in the journal article, Comparing Equals When  
Evaluating Immunotherapy with Different Doses and Fractions  
of Radiation Therapy (Immunotherapy. 2015;7(8):847).
In 2015, Dr. Young was honored by the American Society for 
Clinical Oncology as one of 58 young investigators worldwide  
to receive its prestigious Young Investigator Award. The award 
will fund her translational research proposal, entitled Targeting 
the Tumor Stroma to Enhance Radiation Efficacy, to advance 
state-of-the-art cancer immunotherapy through improving the 
immune response to cancer among patients receiving radiation 
therapy. She was also awarded a Research and Education  
Foundation Seed Grant from the Radiologic Society of North 
America for her proposal Targeting Cancer-Associated Fibroblasts 
to Enhance Radiation Efficacy. 
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Peripheral Blood Mononuclear Cells (PBMC) and serum (left) are isolated 
and stored in liquid nitrogen tanks for use on subsequent assays (right).
The Robert W. Franz Cancer Research Center, founded in 
1993 by Walter J. Urba, M.D., Ph.D., and a small team of 
scientists, is part of the Earle A. Chiles Research Institute 
at Providence Cancer Center. 
Research laboratories  
of the Earle A. Chiles 
Research Institute are  
in close proximity to the 
oncology clinics and 
patient rooms within 
Providence Cancer 
Center so that scientists 
never lose sight of the 
people their research  
is intended to serve.  
This environment 
encourages translational research, also known as bench-to-bedside 
research, where scientists and physicians partner to translate  
the most promising discoveries from the laboratory into novel 
treatments for patients in Oregon and throughout the country. 
The Earle A. Chiles Research Institute is home to state-of-the-art 
core facilities offering the latest in immunological monitoring,  
flow cytometry and molecular pathology and informatics services. 
These facilities are available to both intramural and extramural 
investigators.
Immune Monitoring Laboratory
Established in 2000, the mission of the Immune Monitoring Laboratory 
(IML) is to support clinical investigators and research scientists at  
Providence Cancer Center and throughout the United States by  
providing real-time, state-of-the-art monitoring of cancer patients’ 
immune responses during immunotherapy clinical trials. The IML is also 
the archival and disbursement center for the acquisition, processing, 
cryopreservation and cataloguing of all peripheral blood mononuclear 
cells and serum collected during the course of cancer clinical trials. 
The IML team is among the nation’s leaders in developing and  
implementing immune monitoring assays for the evaluation of  
anti-tumor immune responses in cancer patients receiving  
immunotherapy. They measure patients’ immune responses  
to different anti-cancer immunotherapy interventions, such as  
checkpoint inhibitors, T-cell agonists, and experimental cancer  
vaccines, to assess their effectiveness. They use a variety of  
standardized assays specifically designed and optimized to monitor 
changes and detect responses in cancer patients’ immune systems 
throughout the course of their treatments. 
CORE FACILITIES
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Flow Cytometry Core
The IML encompasses the Flow Cytometry Core, a valuable resource 
to all intramural investigators. Highly sophisticated polychromatic 
flow cytometry techniques allow investigators to measure anti-tumor 
immune responses on a cellular level. The results help researchers 
refine their studies and improve immunotherapy strategies for 
patients at Providence Cancer Center and throughout the world. 
The Flow Cytometry Core provides sample processing, staining, 
data acquisition and analysis under the supervision of experienced 
research personnel who assist in the design and execution of 
multi-color flow cytometry and all sorting experiments.
The Flow Cytometry Core is equipped with a BD LSRII, BD FACS 
Aria II Cell Sorter with BSL2 Containment System, BD FACS Calibur, 
CTL ImmunoSpot ELISpot, Bio-Plex 100 and Guava PCA-96,  
among other state-of-the-art immunological monitoring and  
flow cytometry resources. 
Molecular Pathology Core
The Molecular Pathology 
Laboratory (MPL) is a  
fundamental and strong 
component of translational 
research of the Earle A. 
Chiles Research Institute. 
The MPL provides translational immunologists with molecular 
correlates to their research questions. The MPL leverages  
shared clinical infrastructures dedicated to the deployment  
of a system-wide personalized medicine program enabling 
high-throughput “-omics” projects with clinically validated  
bioinformatics pipelines supported by a dedicated in-house  
software development team. All applications include data security, 
access logs, data storage, and backup and are built to operate in 
the clinical setting. 
The MPL is part of Providence Health  
and Services laboratories, licensed by  
the Oregon State Health Division and 
accredited by various agencies such as  
the College of American Pathologists,  
Joint Commission,  Accreditation of  
Hospitals Organization, American  
Association of Blood Banks and FDA.  
The MPL maintains a significant and  
diverse sequencing infrastructure  
including the latest Illumina and Ion  
Torrent instrumentation as well as instruments for performing 
Sanger sequencing and quantitative polymerase chain reaction 
(PCR). The large-capacity HiSeq 2500 is devoted to exome  
sequencing, RNA-seq and other genomics applications.
Fresh blood is stained with approximately 70 antibodies (left); the 
stained cells are then measured with a flow cytometer (right).
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GRADUATE EDUCATION 
Since 1994, the Earle  
A. Chiles Research Institute 
has trained the next  
generation of tumor  
immunologists. 
Through a partnership with 
Oregon Health & Science 
University School of Medicine, 
graduate students conduct  
research under the mentorship of a faculty member with a joint 
appointment at the School of Medicine and the Earle A. Chiles 
Research Institute. Students accepted into doctoral programs in 
Molecular Microbiology and Immunology, Molecular and Cellular 
Biosciences, and Cancer Biology attend university courses and 
conduct research at the Earle A. Chiles Research Institute in the 
laboratory of their faculty advisor. Students have the opportunity to 
give poster presentations at national conferences and present their 
research at department seminars while advancing to doctoral 
candidacy. Faculty advisors serve as members of the students’ 
thesis committees, guiding them through thesis defense to degree 
completion. Upon receipt of their doctoral degrees, previous  
students have been accepted to postdoctoral fellowships at the 
National Cancer Institute, INSERM (French National Institute of 
Health and Medical Research) and within the biotechnology industry. 
POSTDOCTORAL FELLOWSHIPS 
Earle A. Chiles Research Institute provides a rich  
postdoctoral training environment that stimulates  
creativity and nurtures professionalism for fellows  
pursuing careers in cancer immunotherapy. 
Postdoctoral fellowships serve as training periods of scholarly,  
mentored research for doctoral degree holders seeking to acquire 
the professional skills and experience necessary for independent 
scientific careers. With input and guidance from their faculty  
mentors at the Earle A. Chiles Research Institute, fellows develop 
individualized development plans to identify professional  
development opportunities and career objectives which serve to 
guide them through their fellowships. 
In addition to discipline-specific  
expertise, conceptual knowledge and 
research skill development, fellows  
are also mentored in leadership,  
management, communication, and  
the responsible conduct of research. 
Fellows are encouraged to obtain 
external funding and develop a strong 
publication record to provide a solid 
foundation for transitioning to an 
independent scientific career. Previous postdoctoral fellows have 
received funding from the NIH Pathway to Independence Award 
(K99), American Cancer Society Postdoctoral Fellowship Award,  
and Prostate Cancer Foundation Young Investigator Award, and 
obtained appointments at Rush University, Oregon Health & Science 
University, Legacy Research Institute and the Earle A. Chiles Research 
Institute upon completion of their training fellowships.
EDUCATION & TRAINING
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2015 Summer Research Program Cohort
SUMMER RESEARCH PROGRAM 
The Earle A. Chiles Research Institute offers a summer 
research program for undergraduate students pursuing  
a career in biomedical sciences. 
The intensive nine-week internship is designed to provide direct, 
hands-on research experience and mentorship for undergraduate 
students who are interested in biomedical research. Under the 
guidance of a faculty mentor, interns complete an independent 
research project and present their findings at a capstone poster 
session. Interns also attend regular bioinformatics classes,  
institute-wide research seminars, and Journal Club meetings. 
Research projects and poster presentations from the  
2015 cohort include: 
 • Sting Ligand and its Effect on SOCS Production
 • Soluble Intercellular Signaling Factors in the  
  Tumor Microenvironment
 • Different Therapeutic Anti-PD-1 Clones Prevent or  
  Allow the Detection of PD-1 via Flow Cytometry
 • Cross Presentation of DRibble Vaccine Independent  
  of MyD88 Adaptor Protein
 • OX40 Immunotherapy Effect on Tumor Resident Regulatory  
  T cell Function and Phenotype
Past interns have been 
accepted to Oregon 
Health & Science  
University School of 
Medicine, Northwestern 
University School of 
Medicine, and The Mayo 
Clinic Graduate School.
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CREATING HOPE LUNCHEON 
2015 marked the 17th anniversary of the Creating Hope 
for Cancer Patients Luncheon, the signature fundraising 
event of Providence Cancer Center benefitting the  
Earle A. Chiles Research Institute. 
With more than 540 guests in attendance and a $100,000  
matching challenge, the 17th Annual Creating Hope Luncheon 
garnered a record-breaking $620,000 in contributions. Emceed  
by Matt Zaffino of KGW Channel 8 News, the program included 
remarks from cancer patients and survivors, including a keynote 
address from cancer survivor, cartoonist and author of Cancer 
Vixen, Marisa Acocella Marchetto. Survivors shared stories of their 
treatment and care at Providence Cancer Center and inspired 
hope in others. Walter J. Urba, M.D., Ph.D., director of cancer 
research at the Earle A. Chiles Research Institute, was joined by 
Nick Morris, Ph.D., cancer survivor and senior research scientist,  
in conveying the importance of philanthropy in advancing cancer 
research and immunotherapy. 
FINISH CANCER CAMPAIGN 
The 2015 Creating Hope  
Luncheon served as the  
launch of Providence Cancer 
Center’s award-winning  
#FINISHCANCER campaign. 
Honored with a 2015 Gold  
Award by the Cancer Awareness  
Advertising Awards Program, the 
#FINISHCANCER campaign aims to 
raise awareness of recent advancements in cancer research – 
namely immunotherapy – and the need for continued funding. 
The campaign emphasizes the “I CAN” in “FINISHCANCER,” 
calling on all to help finish the fight against cancer. Whether 
through volunteering, advocacy, donations or promoting cancer 
screenings and prevention, all have a role to play in finishing 
cancer. Visit www.finishcancer.org to learn more.  
EVENTS & ENGAGEMENT
2015 Creating Hope Luncheon speakers (L to R): Mark Williams,  
Luncheon co-chair and cancer survivor; Nick Morris, Ph.D., Weinberg 
Lab scientist and cancer survivor; Marisa Acocella Marchetto, keynote 
speaker; Walter J. Urba, M.D., Ph.D., director, Earle A. Chiles Research 
Institute; Julie Randall, cancer patient with husband Scott; and  
Michelle Judson, cancer survivor with daughter Scarlett. 
Researchers, clinicians, advocates, administrators and support staff wear 
white in support of #WhiteOutCancerDay.
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Runners For Research Van 1 at Timberline 
Lodge.
PROVIDENCE HOOD-TO-COAST RELAY
More than $565,000 was raised for cancer research  
at Providence Cancer Center by participants and  
supporters of the 2015 Hood-To-Coast Relay.  
For the second year in  
a row, Providence Health 
& Services was the title 
sponsor of the world’s 
largest relay race,  
Providence Hood-To-
Coast Relay, spanning 
198 miles from Timberline 
Lodge on Mt. Hood to 
the coastal town of 
Seaside, Ore. Considered 
the “mother of all  
relays,” this two-day event included 12,600 runners comprising  
1,050 teams supported by 3,600 volunteers. 
Several teams from Providence Health & Services competed,  
including Providence Cancer Center team “Runners For Research” 
led by team captain Samantha Kaiser, director of cancer research 
operations at the Earle A. Chiles 
Research Institute. Fellow  
teammates included researchers, 
administrators, providers,  
advocates, patients and  
Providence Oregon CEO,  
Dave Underriner. 
WHITE OUT CANCER DAY
A day devoted to raising awareness of cancer  
immunotherapy, the Earle A. Chiles Research Institute 
joined institutions across the world in celebrating 
#WhiteOutCancerDay. 
On June 12, 2015, Providence researchers stood side by side  
with oncologists, nurses, fundraising officers, administrators and  
support staff to show support for cancer immunotherapy, shared 
via Providence Cancer Center social media using hashtags  
#WhiteOutCancer and #FinishCancer.
Runners For Research Van 2 at 
Providence Cancer Center.
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2015 Franz Leadership Cabinet with ex-officio members Bernard A. Fox, 
Ph.D., and Walter J. Urba, M.D., Ph.D., pictured second row far left and 
far right, respectively. Not all members pictured.
33
The Robert W. Franz Leadership Cabinet comprises  
men and women with a strong desire to connect our 
local community with dedicated teams of researchers  
at the Earle A. Chiles Research Institute working to  
finish cancer.
Founded in 2001, the leadership cabinet has a strong and loyal 
membership representing a broad spectrum of the community.
2015 CABINET MEMBERS
Charlie Engleberg, Chair
Flo Atkinson
Stephen Bader, M.D.
Mark Beckius
Walter Bowen
Earle M. Chiles
Maxine Cracraft
Dan Floyd
Robert W. Franz
Diana Hall
Cindy Harder
FRANZ LEADERSHIP CABINET
At the Earle A. Chiles Research Institute, 
scientists work in lockstep with physicians  
to discover ways to harness our own immune 
systems in the fight against cancer. “I continue 
to be amazed by the number of times  
researchers at the Earle A. Chiles Institute 
have been first in Oregon, first in the country, 
even first in the world, to deliver novel  
treatments to patients,” says Charlie  
Engleberg. “Cancer immunotherapy is  
proving to save lives!” 
Tyler Johnson
Sheryl Langerman Rosenfeld
Lynn Loacker
TJ O’Connor
Linda Read
James F. Robb, Ph.D.
Linda Smiley
Jim Snow
Judi Swift
Mark Williams
Linda Yoshida
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